187 216

Cited 1 times in

Height outcomes in Korean children with idiopathic short stature receiving growth hormone treatment

 Hyun Wook Chae  ;  Il-Tae Hwang  ;  Ji-Eun Lee  ;  Cheol Hwan So  ;  Young-Jun Rhie  ;  Jung Sub Lim  ;  Eun Byul Kwon  ;  Kyung Hee Yi  ;  Eun Young Kim  ;  Chae-Ku Jo  ;  Kye Shik Shim  ;  Ha-Yeong Gil  ;  Min-Jeong Seong  ;  Chung Mo Nam  ;  Ji-Su Moon  ;  Jin Soon Hwang 
 FRONTIERS IN ENDOCRINOLOGY, Vol.13 : 925102, 2022-09 
Journal Title
Issue Date
Body Height ; Child ; Female ; Growth Disorders* / drug therapy ; Growth Hormone / pharmacology ; Human Growth Hormone* ; Humans ; Male ; Retrospective Studies
GH device type ; ISS (idiopathic short stature) ; Korean ISS (idiopathic short stature) patients ; dose of growth hormone ; growth hormone ; height velocity
Objectives: Growth hormone (GH) therapy's capacity to increase height velocity and height at the end of the study in children with idiopathic short stature (ISS) is controversial. We aimed to investigate the height standard deviation score (SDS) and height velocity of patients with ISS in Korea who received GH treatment.

Methods: We retrospectively reviewed and performed linear mixed model and survival analyses on data from 12 tertiary hospitals in Korea, including subjects diagnosed with ISS from January 2009 to September 2019, treated with GH therapy for more than 6 months, and who were at a pre-pubertal state at the time of diagnosis.

Results: We included 578 children (330 boys and 248 girls). The mean daily dose of GH in this study was 0.051 mg/kg, which was lower than the approved dose in Korea of 0.062 - 0.067 mg/kg. Height SDS was higher in patients who started treatment before the age of 6 years. The probability of reaching the target SDS (-1 SDS) from the beginning of treatment to 2-3 years after its start was higher in children starting treatment before the age of 6 years. The hazard ratio to reach the target SDS (-1 SDS) when using automatic pen or electronic devices was 1.727 times higher than that when using the needle and syringe device.

Conclusion: ISS patients should start GH treatment at an early age, and even lower-than-recommended drug doses may be effective. The selection of automatic pen or electronic device can have a positive effect on reaching the target height SDS.
Files in This Item:
T202204932.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine (예방의학교실) > 1. Journal Papers
Yonsei Authors
Nam, Chung Mo(남정모) ORCID logo https://orcid.org/0000-0003-0985-0928
Chae, Hyun Wook(채현욱) ORCID logo https://orcid.org/0000-0001-5016-8539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.